Particle.news
Download on the App Store
5 ARTICLES
·
3w ago

FDA and EPA Advance Plans to Phase Out Animal Testing in Favor of Human-Relevant Methods

New policies under the Trump administration aim to modernize drug and chemical testing with AI and lab-grown organ models, reducing costs and animal use.

PETA commends the Trump administration's efforts to phase out animal testing in federal research, with the FDA moving to adopt more ethical methods like organoids.
Image
Activists of the People for the Ethical Treatment of Animals (PETA) hold placards which read "Sanofi: Stop the mad scientists, Stop the forced swimming tests" as they protest against animal testing by French multinational pharmaceutical and healthcare company Sanofi on the sidelines of the company's general assembly at the Palais des Congres in Paris, on April 30, 2024. (Photo by Antonin UTZ / AFP) (Photo by ANTONIN UTZ/AFP via Getty Images)
Image

Overview

  • The FDA announced a roadmap to phase out animal testing for monoclonal antibody therapies, replacing it with advanced human-relevant methods like AI modeling and organoid testing.
  • The Environmental Protection Agency (EPA) reinstated its commitment to reduce mammalian testing by 30% by 2025 and eliminate it entirely by 2035.
  • FDA Commissioner Martin Makary emphasized that the shift will improve drug safety, accelerate treatment approvals, and lower research and development costs.
  • Animal rights organization PETA praised the initiative, calling it a significant step toward ending animal testing and embracing modern scientific approaches.
  • The Trump administration's efforts build on the FDA Modernization Act 2.0 from 2023, signaling a broader regulatory and ethical commitment to innovation in drug and chemical testing.